• Bone Health
  • Immunology
  • Hematology
  • Respiratory
  • Dermatology
  • Diabetes
  • Gastroenterology
  • Neurology
  • Oncology
  • Ophthalmology
  • Rare Disease
  • Rheumatology

Molly Burich Discusses the Lack of Interchangeable Biosimilars


Molly Burich, MS, head of public policy at Boehringer Ingelheim, discusses the why there currently are no biosimilars with an interchangeability designation during the World Biosimilar Congress USA 2020 at the Festival of Biologics USA in San Diego, California..

Molly Burich, MS, is the head of public policy at Boehringer Ingelheim.


So far, there are no interchangeable biosimilars. Why is that?

The reason why we don't have any interchangeable biosimilars yet is because all that are launched are on the medical benefit side, meaning they're administered by the physician. And without that pharmacy interplay, there's really no need to have an interchangeability designation because that really is the primary goal of that designation, is to allow for that. When a physician is managing their own inventory and managing the switch, there is no pharmacy interaction. So, we haven't seen interchangeable[s] yet because, right now, we don't have any pharmacy benefit—approved biosimilars.

Related Videos
Lakesha Farmer, PharmD
Lakesha Farmer from Cencora
Jeffrey Casberg, RPh, MS.
Adam Colborn, JD.
Legal scale weighs profit as greater than medical treatment
Ha Kung Wong, JD.
Ha Kung Wong, JD
Cencora's Corey Ford
Related Content
© 2024 MJH Life Sciences

All rights reserved.